Skip directly to Accessibility Notice

BBH
VanEck Biotech ETF

Fund Description

VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS®US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

 
 

  • Fund Ticker

    BBH

  • Exchange

    NASDAQ

  • Inception Date

    12/20/2011

  • ETF Structure

    Physical

  • Administrator

    Van Eck Associates

  • Index Ticker

    MVBBHTR

  • Index Rebalancing

    Quarterly

 
as of 07/01/22

  • 30-Day SEC Yield

    0.52%

  • Total Net Assets

    $458.1M

  • Number of Holdings

    25

  • Options

    Available

  • Gross Expense Ratio2

    0.35%

  • Net Expense Ratio/TER2

    0.35%

  • Distribution Frequency

    Annual

  • Next Distribution Date

    12/16/2022
Schedule a Call
How to Buy

Key Points

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market cap and trading volume

  • Industry Leaders 
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation

Trading Information

  • Fund Ticker

    BBH

  • Index Total Return Ticker

    MVBBHTR

  • NAV

    BBHNV

  • Intraday NAV (IIV)4

    BBHIV

  • Shares Outstanding

    3,071,503

  • Estimated Cash

    BBHEU

  • Total Cash

    BBHTC

  • CUSIP

    92189F726

  • ISIN

    US92189F7261
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.35%

  • Other Expenses

    --

  • Acquired Fund Fees and Expenses

    --

  • Gross Expense Ratio

    0.35%

  • Fee Waivers and
    Expense Reimbursement

    --

  • Net Expense Ratio/TER2

    0.35%

2'Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2023.'

Investment Professionals

  • Portfolio Manager and Head of Equity ETFs
  • Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
  • Joined VanEck in 2005
  • CFA charterholder; member of the CFA Society New York
  • BA, Mathematics and Economics, New York University
  • Portfolio Manager and Analyst for Equity ETFs
  • Joined VanEck in 2007
  • Prior to his current role, held a portfolio administration position at VanEck
  • Previously, Portfolio Analyst at Evaluation Associates
  • BS, Business Administration (concentration in Financial Analysis), State University of New York at Buffalo
  • Analyst for Equity ETFs
  • Joined VanEck in 2018
  • Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
  • BS, Finance, Providence College
  • Analyst for Equity ETFs
  • Joined VanEck in 2019
  • Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
  • BS, Accounting, Hunter College

Prices as of 07/01/22

NAV/
Market
Price 		Volume
30-Day Avg./
Last Trading Day 		Daily Change
NAV/
Last Price 		YTD Change NAV/
Last Price 		Premium/
Discount 		30-Day
Median
Bid Ask
Spread 		NAV
Chart
BBH $149.13
$149.08 		28,561
10,088 		$3.16 / +2.16%
$3.29 / +2.26% 		-21.21%
-21.26% 		$-0.05
-0.03% 		0.10%

Premium/Discount History as of 07/01/22

Calendar Year 2021 3Q 2021 4Q 2021 1Q 2022 2Q 2022 Premium/Discount Charts NAV & Prem/Discount History
Days closed at a premium 135 31 38 32 27
BBH Days closed at NAV 1 0 0 0 0
Days closed at a discount 116 33 26 30 35

Performance History: Average Annual Total Returns* (%)
View All ETFs View All Indices

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
BBH (NAV) 1.08 -5.83 -21.76 -19.35 8.67 5.18 12.89 15.03
BBH (Share Price) 1.10 -5.77 -21.84 -19.47 8.63 5.16 12.88 15.04
MVBBHTR (Index) 1.08 -5.80 -21.75 -19.24 8.81 5.36 13.07 15.22
Performance Differential (NAV - Index) -- -0.03 -0.01 -0.11 -0.14 -0.18 -0.18 -0.19
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
BBH (NAV) 3.21 -14.25 -14.25 -7.17 8.43 6.79 14.17 16.33
BBH (Share Price) 3.23 -14.37 -14.37 -7.39 8.39 6.79 14.13 16.33
MVBBHTR (Index) 3.23 -14.25 -14.25 -7.02 8.58 6.97 14.34 16.52
Performance Differential (NAV - Index) -0.02 -- -- -0.15 -0.15 -0.18 -0.17 -0.19

*Returns less than one year are not annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

The "Net Asset Value" (NAV) of a Fund is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell shares at NAV.

Top 10 Holdings (%) as of 05/31/22 Daily Holdings

Total Holdings: 25
Swipe
to view
full data
Holding Name
Ticker
Shares
 Market Value
(US$) 		% of Net
Assets
Amgen Inc
AMGN US
262,022
 67,271,528 15.16
Gilead Sciences Inc
GILD US
541,339
 35,105,834 7.91
Vertex Pharmaceuticals Inc
VRTX US
126,312
 33,933,719 7.65
Moderna Inc
MRNA US
215,468
 31,313,964 7.06
Regeneron Pharmaceuticals Inc
REGN US
46,072
 30,625,901 6.90
Iqvia Holdings Inc
IQV US
104,356
 22,462,629 5.06
Biontech Se
BNTX US
135,908
 22,201,931 5.00
Biogen Inc
BIIB US
101,786
 20,357,200 4.59
Seagen Inc
SGEN US
134,349
 18,228,472 4.11
Bio-Techne Corp
TECH US
47,713
 17,640,927 3.98
Top 10 Total (%) 67.41
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 05/31/22

  • Country

    % of Net Assets
  • ■

    United States

    87.61
  • ■

    Germany

    5.00
  • ■

    Ireland

    3.27
  • ■

    China

    2.92
  • ■

    Switzerland

    1.21
  • ■

    Other/Cash

    -0.01

Sector Weightings (%) as of 05/31/22

  • Sector

    % of Net Assets
  • ■

    Health Care

    100.0
  • ■

    Other/Cash

    0.0